vs

Side-by-side financial comparison of APTARGROUP, INC. (ATR) and FactSet (FDS). Click either name above to swap in a different company.

APTARGROUP, INC. is the larger business by last-quarter revenue ($962.7M vs $607.6M, roughly 1.6× FactSet). FactSet runs the higher net margin — 25.1% vs 7.7%, a 17.4% gap on every dollar of revenue. On growth, APTARGROUP, INC. posted the faster year-over-year revenue change (13.5% vs 6.9%). APTARGROUP, INC. produced more free cash flow last quarter ($96.9M vs $90.4M). Over the past eight quarters, FactSet's revenue compounded faster (5.5% CAGR vs 2.6%).

AptarGroup, Inc., also known as Aptar, is a United States–based global manufacturer of consumer dispensing packaging and drug delivery devices. The group has manufacturing operations in 18 countries.

FactSet Research Systems Inc., trading as FactSet, is an American financial data and software company headquartered in Norwalk, Connecticut, United States. The company provides integrated data and software. For fiscal year 2024, FactSet's total ASV and professional services revenues were $2.2 billion. FactSet's total market value is approximately $17 billion.

ATR vs FDS — Head-to-Head

Bigger by revenue
ATR
ATR
1.6× larger
ATR
$962.7M
$607.6M
FDS
Growing faster (revenue YoY)
ATR
ATR
+6.7% gap
ATR
13.5%
6.9%
FDS
Higher net margin
FDS
FDS
17.4% more per $
FDS
25.1%
7.7%
ATR
More free cash flow
ATR
ATR
$6.4M more FCF
ATR
$96.9M
$90.4M
FDS
Faster 2-yr revenue CAGR
FDS
FDS
Annualised
FDS
5.5%
2.6%
ATR

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ATR
ATR
FDS
FDS
Revenue
$962.7M
$607.6M
Net Profit
$74.3M
$152.6M
Gross Margin
52.6%
Operating Margin
11.0%
31.6%
Net Margin
7.7%
25.1%
Revenue YoY
13.5%
6.9%
Net Profit YoY
-26.4%
1.7%
EPS (diluted)
$1.13
$4.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATR
ATR
FDS
FDS
Q4 25
$962.7M
$607.6M
Q3 25
$961.1M
$596.9M
Q2 25
$966.0M
$585.5M
Q1 25
$887.3M
$570.7M
Q4 24
$848.1M
$568.7M
Q3 24
$909.3M
$562.2M
Q2 24
$910.1M
$552.7M
Q1 24
$915.4M
$545.9M
Net Profit
ATR
ATR
FDS
FDS
Q4 25
$74.3M
$152.6M
Q3 25
$127.9M
$153.6M
Q2 25
$111.7M
$148.5M
Q1 25
$78.8M
$144.9M
Q4 24
$100.9M
$150.0M
Q3 24
$100.0M
$89.5M
Q2 24
$90.5M
$158.1M
Q1 24
$83.1M
$140.9M
Gross Margin
ATR
ATR
FDS
FDS
Q4 25
52.6%
Q3 25
51.6%
Q2 25
52.1%
Q1 25
52.8%
Q4 24
54.5%
Q3 24
54.1%
Q2 24
55.3%
Q1 24
53.3%
Operating Margin
ATR
ATR
FDS
FDS
Q4 25
11.0%
31.6%
Q3 25
14.2%
29.7%
Q2 25
14.9%
33.2%
Q1 25
12.8%
32.5%
Q4 24
14.2%
33.6%
Q3 24
15.2%
22.7%
Q2 24
13.8%
36.6%
Q1 24
12.2%
33.3%
Net Margin
ATR
ATR
FDS
FDS
Q4 25
7.7%
25.1%
Q3 25
13.3%
25.7%
Q2 25
11.6%
25.4%
Q1 25
8.9%
25.4%
Q4 24
11.9%
26.4%
Q3 24
11.0%
15.9%
Q2 24
9.9%
28.6%
Q1 24
9.1%
25.8%
EPS (diluted)
ATR
ATR
FDS
FDS
Q4 25
$1.13
$4.06
Q3 25
$1.92
$4.03
Q2 25
$1.67
$3.87
Q1 25
$1.17
$3.76
Q4 24
$1.48
$3.89
Q3 24
$1.48
$2.33
Q2 24
$1.34
$4.09
Q1 24
$1.23
$3.65

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATR
ATR
FDS
FDS
Cash + ST InvestmentsLiquidity on hand
$409.5M
$292.7M
Total DebtLower is stronger
$1.1B
$1.4B
Stockholders' EquityBook value
$2.7B
$2.2B
Total Assets
$5.3B
$4.2B
Debt / EquityLower = less leverage
0.43×
0.63×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATR
ATR
FDS
FDS
Q4 25
$409.5M
$292.7M
Q3 25
$264.8M
$355.1M
Q2 25
$169.8M
$364.0M
Q1 25
$136.8M
$287.0M
Q4 24
$226.2M
$358.8M
Q3 24
$327.9M
$492.6M
Q2 24
$223.9M
$522.0M
Q1 24
$201.1M
$450.2M
Total Debt
ATR
ATR
FDS
FDS
Q4 25
$1.1B
$1.4B
Q3 25
$546.0M
$1.4B
Q2 25
$535.1M
$1.4B
Q1 25
$561.2M
$1.5B
Q4 24
$688.1M
$1.4B
Q3 24
$822.7M
$1.4B
Q2 24
$681.5M
$1.4B
Q1 24
$680.4M
$1.5B
Stockholders' Equity
ATR
ATR
FDS
FDS
Q4 25
$2.7B
$2.2B
Q3 25
$2.8B
$2.2B
Q2 25
$2.7B
$2.2B
Q1 25
$2.5B
$2.1B
Q4 24
$2.5B
$2.0B
Q3 24
$2.5B
$1.9B
Q2 24
$2.4B
$1.9B
Q1 24
$2.3B
$1.8B
Total Assets
ATR
ATR
FDS
FDS
Q4 25
$5.3B
$4.2B
Q3 25
$5.1B
$4.3B
Q2 25
$4.9B
$4.3B
Q1 25
$4.5B
$4.2B
Q4 24
$4.4B
$4.0B
Q3 24
$4.6B
$4.1B
Q2 24
$4.5B
$4.0B
Q1 24
$4.4B
$4.0B
Debt / Equity
ATR
ATR
FDS
FDS
Q4 25
0.43×
0.63×
Q3 25
0.20×
0.63×
Q2 25
0.20×
0.66×
Q1 25
0.22×
0.72×
Q4 24
0.28×
0.68×
Q3 24
0.32×
0.71×
Q2 24
0.28×
0.76×
Q1 24
0.29×
0.83×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATR
ATR
FDS
FDS
Operating Cash FlowLast quarter
$183.7M
$121.3M
Free Cash FlowOCF − Capex
$96.9M
$90.4M
FCF MarginFCF / Revenue
10.1%
14.9%
Capex IntensityCapex / Revenue
9.0%
5.1%
Cash ConversionOCF / Net Profit
2.47×
0.79×
TTM Free Cash FlowTrailing 4 quarters
$299.6M
$647.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATR
ATR
FDS
FDS
Q4 25
$183.7M
$121.3M
Q3 25
$177.6M
$212.1M
Q2 25
$126.0M
$253.8M
Q1 25
$82.7M
$174.0M
Q4 24
$178.2M
$86.4M
Q3 24
$229.3M
$163.2M
Q2 24
$143.6M
$238.2M
Q1 24
$92.3M
$143.8M
Free Cash Flow
ATR
ATR
FDS
FDS
Q4 25
$96.9M
$90.4M
Q3 25
$114.3M
$178.1M
Q2 25
$62.5M
$228.6M
Q1 25
$25.9M
$150.2M
Q4 24
$112.2M
$60.5M
Q3 24
$162.7M
$137.2M
Q2 24
$75.4M
$216.9M
Q1 24
$16.7M
$121.9M
FCF Margin
ATR
ATR
FDS
FDS
Q4 25
10.1%
14.9%
Q3 25
11.9%
29.8%
Q2 25
6.5%
39.0%
Q1 25
2.9%
26.3%
Q4 24
13.2%
10.6%
Q3 24
17.9%
24.4%
Q2 24
8.3%
39.2%
Q1 24
1.8%
22.3%
Capex Intensity
ATR
ATR
FDS
FDS
Q4 25
9.0%
5.1%
Q3 25
6.6%
5.7%
Q2 25
6.6%
4.3%
Q1 25
6.4%
4.2%
Q4 24
7.8%
4.5%
Q3 24
7.3%
4.6%
Q2 24
7.5%
3.9%
Q1 24
8.3%
4.0%
Cash Conversion
ATR
ATR
FDS
FDS
Q4 25
2.47×
0.79×
Q3 25
1.39×
1.38×
Q2 25
1.13×
1.71×
Q1 25
1.05×
1.20×
Q4 24
1.77×
0.58×
Q3 24
2.29×
1.82×
Q2 24
1.59×
1.51×
Q1 24
1.11×
1.02×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ATR
ATR

Pharma Segment$833.1M87%
Other$129.6M13%

FDS
FDS

Americas Segment$399.7M66%
EMEA Segment$149.1M25%
Asia Pacific Segment$62.2M10%

Related Comparisons